Trials / Completed
CompletedNCT01184846
Study of Efficacy and Safety of Privigen in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy
A Single-arm Study to Demonstrate the Efficacy and Safety of Privigen in the Treatment of Subjects With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 31 (actual)
- Sponsor
- CSL Behring · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this study is to demonstrate the efficacy and safety of Privigen in subjects with CIDP.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | 10% liquid formulation of human immunoglobulin |
Timeline
- Start date
- 2010-11-01
- Primary completion
- 2011-11-01
- Completion
- 2011-11-01
- First posted
- 2010-08-19
- Last updated
- 2024-06-25
- Results posted
- 2013-04-04
Locations
22 sites across 5 countries: Belgium, Finland, France, Germany, Poland
Source: ClinicalTrials.gov record NCT01184846. Inclusion in this directory is not an endorsement.